HUE063778T2 - FcRn ellenanyagok és eljárások alkalmazásukra - Google Patents
FcRn ellenanyagok és eljárások alkalmazásukraInfo
- Publication number
- HUE063778T2 HUE063778T2 HUE16744204A HUE16744204A HUE063778T2 HU E063778 T2 HUE063778 T2 HU E063778T2 HU E16744204 A HUE16744204 A HU E16744204A HU E16744204 A HUE16744204 A HU E16744204A HU E063778 T2 HUE063778 T2 HU E063778T2
- Authority
- HU
- Hungary
- Prior art keywords
- methods
- fcrn antibodies
- fcrn
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110071P | 2015-01-30 | 2015-01-30 | |
| US201562258082P | 2015-11-20 | 2015-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE063778T2 true HUE063778T2 (hu) | 2024-01-28 |
Family
ID=56544538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16744204A HUE063778T2 (hu) | 2015-01-30 | 2016-01-29 | FcRn ellenanyagok és eljárások alkalmazásukra |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10676526B2 (enExample) |
| EP (2) | EP4286011A3 (enExample) |
| JP (2) | JP6853178B2 (enExample) |
| KR (3) | KR20250052465A (enExample) |
| CN (13) | CN118562003A (enExample) |
| AU (2) | AU2016211280B2 (enExample) |
| DK (1) | DK3250610T3 (enExample) |
| ES (1) | ES2962824T3 (enExample) |
| FI (1) | FI3250610T3 (enExample) |
| HR (1) | HRP20231399T1 (enExample) |
| HU (1) | HUE063778T2 (enExample) |
| IL (1) | IL252837B (enExample) |
| LT (1) | LT3250610T (enExample) |
| NZ (1) | NZ772383A (enExample) |
| PL (1) | PL3250610T3 (enExample) |
| PT (1) | PT3250610T (enExample) |
| RS (1) | RS64768B1 (enExample) |
| SG (2) | SG10202007232WA (enExample) |
| SI (1) | SI3250610T1 (enExample) |
| SM (1) | SMT202300365T1 (enExample) |
| WO (1) | WO2016123521A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201605203UA (en) | 2013-12-24 | 2016-07-28 | Argen X N V | Fcrn antagonists and methods of use |
| RU2714153C2 (ru) * | 2014-06-12 | 2020-02-12 | Ф. Хоффманн-Ля Рош Аг | СПОСОБ ОТБОРА АНТИТЕЛ С МОДИФИЦИРОВАННЫМ ВЗАИМОДЕЙСТВИЕМ С FcRn |
| CN118562003A (zh) | 2015-01-30 | 2024-08-30 | 动量制药公司 | Fcrn抗体及其使用方法 |
| DK3491025T3 (da) * | 2016-07-29 | 2024-01-15 | Momenta Pharmaceuticals Inc | Fcrn-antistoffer og anvendelsesmetoder heraf |
| EP3638305A1 (en) * | 2017-06-15 | 2020-04-22 | UCB Biopharma SRL | Method for the treatment of immune thrombocytopenia |
| EP3720877A1 (en) | 2017-12-08 | 2020-10-14 | Argenx BVBA | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| AU2018386193B2 (en) * | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| AU2019283673B2 (en) | 2018-06-08 | 2023-12-07 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| EP3823978A4 (en) * | 2018-07-20 | 2022-12-14 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
| SG11202100420UA (en) * | 2018-07-20 | 2021-02-25 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| CN113646051A (zh) | 2018-10-16 | 2021-11-12 | Ucb生物制药有限责任公司 | 重症肌无力的治疗方法 |
| MX2021014756A (es) | 2019-06-07 | 2022-01-18 | Argenx Bvba | Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea. |
| CN114630678A (zh) * | 2019-08-01 | 2022-06-14 | 詹森生物科技公司 | FcRn抗体及其使用方法 |
| MX2022005862A (es) * | 2019-11-19 | 2022-06-23 | Immunovant Sciences Gmbh | Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn. |
| CN115836086A (zh) | 2020-01-08 | 2023-03-21 | 阿尔金克斯有限公司 | 治疗天疱疮病症的方法 |
| IL302516A (en) * | 2020-11-06 | 2023-07-01 | Janssen Biotech Inc | FCRN antibodies and methods of using them |
| WO2022166900A1 (en) * | 2021-02-02 | 2022-08-11 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric fcrn |
| WO2023016538A1 (en) * | 2021-08-13 | 2023-02-16 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing fcrn and uses thereof |
| WO2023030501A1 (zh) * | 2021-09-03 | 2023-03-09 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN119013043A (zh) | 2022-05-30 | 2024-11-22 | 韩兀生物制药股份有限公司 | 具有改善的稳定性的抗FcRn抗体或其抗原结合片段 |
| JP2025520431A (ja) | 2022-06-15 | 2025-07-03 | アルジェニクス ビーブイ | Ｆｃｒｎ／抗原結合分子及び使用方法 |
| TW202444412A (zh) | 2023-02-04 | 2024-11-16 | 美商默門塔醫藥公司 | 用於治療胎兒及新生兒溶血性疾病之組成物及方法 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068259A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| JP2007501847A (ja) * | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| US20090110681A1 (en) | 2005-03-08 | 2009-04-30 | Pfizer, Inc. | Anti-M-CSF Antibody Compositions |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| CN101421297A (zh) * | 2006-02-17 | 2009-04-29 | 森托尼克斯制药有限公司 | 阻断lgG对FcRn的结合的肽 |
| CA2644405A1 (en) * | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| SG10201804513WA (en) * | 2008-04-25 | 2018-07-30 | Dyax Corp | Antibodies Against Fcrn And Use Thereof |
| JP5683581B2 (ja) * | 2009-06-30 | 2015-03-11 | リサーチ ディベロップメント ファウンデーション | 免疫グロブリンＦｃポリペプチド |
| CN105622754B (zh) * | 2011-06-02 | 2019-12-27 | 戴埃克斯有限公司 | Fc受体结合蛋白 |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| WO2014099636A1 (en) | 2012-12-18 | 2014-06-26 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-tnf alpha antibody |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| CN118562003A (zh) | 2015-01-30 | 2024-08-30 | 动量制药公司 | Fcrn抗体及其使用方法 |
| MY188761A (en) | 2015-03-09 | 2021-12-29 | Argenx Bvba | Method of reducing serum levels of fc-containing agents using fcrn antagonists |
| WO2016183352A1 (en) | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| DK3491025T3 (da) | 2016-07-29 | 2024-01-15 | Momenta Pharmaceuticals Inc | Fcrn-antistoffer og anvendelsesmetoder heraf |
| EP3720877A1 (en) | 2017-12-08 | 2020-10-14 | Argenx BVBA | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| AU2018386193B2 (en) | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| SG11202100420UA (en) | 2018-07-20 | 2021-02-25 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| EP3823978A4 (en) | 2018-07-20 | 2022-12-14 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
-
2016
- 2016-01-29 CN CN202410661144.5A patent/CN118562003A/zh active Pending
- 2016-01-29 CN CN202410661140.7A patent/CN118667010A/zh active Pending
- 2016-01-29 WO PCT/US2016/015720 patent/WO2016123521A2/en not_active Ceased
- 2016-01-29 HR HRP20231399TT patent/HRP20231399T1/hr unknown
- 2016-01-29 SG SG10202007232WA patent/SG10202007232WA/en unknown
- 2016-01-29 KR KR1020257010788A patent/KR20250052465A/ko active Pending
- 2016-01-29 EP EP23189767.9A patent/EP4286011A3/en active Pending
- 2016-01-29 NZ NZ772383A patent/NZ772383A/en unknown
- 2016-01-29 EP EP16744204.5A patent/EP3250610B1/en active Active
- 2016-01-29 CN CN202410661136.0A patent/CN118638230A/zh active Pending
- 2016-01-29 CN CN201680008485.6A patent/CN107567460B/zh active Active
- 2016-01-29 CN CN202410661152.XA patent/CN118667015A/zh active Pending
- 2016-01-29 RS RS20231028A patent/RS64768B1/sr unknown
- 2016-01-29 CN CN202410661149.8A patent/CN118667013A/zh active Pending
- 2016-01-29 ES ES16744204T patent/ES2962824T3/es active Active
- 2016-01-29 FI FIEP16744204.5T patent/FI3250610T3/fi active
- 2016-01-29 PT PT167442045T patent/PT3250610T/pt unknown
- 2016-01-29 DK DK16744204.5T patent/DK3250610T3/da active
- 2016-01-29 CN CN202110605791.0A patent/CN113384693B/zh active Active
- 2016-01-29 SM SM20230365T patent/SMT202300365T1/it unknown
- 2016-01-29 KR KR1020227045647A patent/KR102792441B1/ko active Active
- 2016-01-29 HU HUE16744204A patent/HUE063778T2/hu unknown
- 2016-01-29 CN CN202410661142.6A patent/CN118667011A/zh active Pending
- 2016-01-29 JP JP2017539428A patent/JP6853178B2/ja active Active
- 2016-01-29 PL PL16744204.5T patent/PL3250610T3/pl unknown
- 2016-01-29 CN CN202410661150.0A patent/CN118667014A/zh active Pending
- 2016-01-29 SG SG11201705475QA patent/SG11201705475QA/en unknown
- 2016-01-29 CN CN202410661147.9A patent/CN118667012A/zh active Pending
- 2016-01-29 CN CN202410661138.XA patent/CN118652337A/zh active Pending
- 2016-01-29 KR KR1020177024165A patent/KR102483016B1/ko active Active
- 2016-01-29 CN CN202410661131.8A patent/CN118638229A/zh active Pending
- 2016-01-29 CN CN202410661133.7A patent/CN118667009A/zh active Pending
- 2016-01-29 LT LTEPPCT/US2016/015720T patent/LT3250610T/lt unknown
- 2016-01-29 SI SI201631739T patent/SI3250610T1/sl unknown
- 2016-01-29 AU AU2016211280A patent/AU2016211280B2/en active Active
- 2016-01-29 US US15/546,870 patent/US10676526B2/en active Active
-
2017
- 2017-06-11 IL IL252837A patent/IL252837B/en unknown
-
2020
- 2020-03-20 US US16/825,066 patent/US11732047B2/en active Active
-
2021
- 2021-01-12 JP JP2021002601A patent/JP7224382B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201145A patent/AU2022201145B2/en active Active
-
2023
- 2023-07-13 US US18/351,827 patent/US20240158508A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304117A (en) | Anti-pvrig antibodies and methods of use | |
| IL252837A0 (en) | fcrn antibodies and methods of using them | |
| IL259495A (en) | Antibodies and methods for using them | |
| IL257636A (en) | Anti-tigit antibodies and methods of use | |
| IL254887A0 (en) | Anti-sortilin antibodies and methods of using them | |
| SG11201803567XA (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
| SMT202400004T1 (it) | Anticorpi fcrn e loro metodi di utilizzo | |
| ZA202001985B (en) | Anti-htra1 antibodies and methods of use thereof |